3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Suspended
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Meningioma
1
Interventions
Specimen Handling
16
Biopsy
11
Magnetic Resonance Spectroscopy
10
Taxes
4
Bevacizumab
4
Cyclophosphamide
3
Cetuximab
3
olaparib
2
decitabine and cedazuridine drug combination
2
Vincristine
2
Prednisone
2
Paclitaxel
2
Immunoglobulin G
2
Gemcitabine
2
Doxorubicin
2
Disulfides
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
(225)Ac-DOTA-c(RGDyK)
2
zimberelimab
1
zanubrutinib
1
trastuzumab deruxtecan
1
taletrectinib
1
spartalizumab
1
sotigalimab
1
relatlimab
1
regorafenib
1
prednylidene
1
neratinib
1
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Hydroxyurea
×
30 days
×
Clear all
NCT06955169
2026-05-22
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2
Suspended
153 enrolled